Arcus Biosciences, Inc. (RCUS)

In August 2025, Arcus Biosciences announced its participation in investor conferences. In October 2025, the company reported its third-quarter financial results with revenues of $26 million and unveiled its I&I portfolio. In November 2025, Arcus Biosciences completed a $269.7 million stock offering and issued Q3 2025 earnings. In December 2025, UBS Group reiterated a "buy" rating, HC Wainwright raised its target price, and the STAR-221 study was discontinued. In January 2026, Wall Street Zen upgraded shares to "hold," Goldman Sachs Group upgraded to "buy," and President Juan C. Jaen sold shares. In February 2026, Wall Street Zen downgraded Arcus Biosciences to "sell," but the analyst consensus remained a "Moderate Buy."

As a clinical-stage biopharmaceutical company, Arcus Biosciences does not have commercialized products with direct product sales, so traditional demand seasonality is not applicable. Its revenue is primarily generated through strategic collaboration and licensing agreements. Its financial performance is tied to the progress of its drug pipeline.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing cancer immunotherapies. Their research platform centers on modulating tumor microenvironments and immune checkpoints using small-molecule and antibody-based candidates. The company is expanding its focus into immunology and inflammation, with five new research programs disclosed as of October 2025. Key products in their pipeline include etrumadenant, domvanalimab, casdatifan, quemliclustat, zimberelimab, AB598, and AB801.

Arcus Biosciences is headquartered in Hayward, California, and conducts global clinical trials with international collaborations. Taiho holds development and commercial rights for some of Arcus's medicines in Japan and other Asian countries, excluding China.

Arcus Biosciences is known for its focus on developing differentiated molecules and combination therapies for cancer and, more recently, inflammatory and autoimmune diseases. The company's collaboration with Gilead Sciences, Inc. provides financial and development support. The discontinuation of the STAR-221 study could be perceived negatively, while the expansion into I&I and positive clinical data readouts contribute positively to the company's reputation. Analyst ratings remain generally favorable.

Arcus Biosciences is primarily controlled by institutional investors and Gilead Sciences, Inc. Institutional investors hold over 50% of the company, with major shareholders including Gilead Sciences Inc., BlackRock, Inc., and Vanguard Group Inc. Individual investors and non-institutional public companies hold approximately 3.60% of shares. Insiders, including co-founders and Gilead Sciences, Inc., hold a significant block of shares.